JAKARTA, INDONESIA--(Marketwire - Sep 10, 2012) - Moments ago, DividendSeeker.net introduced new coverage of Gilead Sciences, Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN). Full outlook, analysis and consensus opinion is available to readers via the links below.
The consistent delivery of accurate analyses relies solely on two factors, namely: market awareness and industry insight. Recent market drivers include August's contraction of U.S. manufacturing activity, an upward surprise of 0.4% in seasonally-adjusted house prices and the unexpected decline in construction spending. When it comes to discovering the right edge at the right time, all these factors play into effect. For a deeper understanding of the mechanics behind these events and how it can affect your portfolio, please refer to our email newsletter delivered to your inbox.
Dividend Seeker is releasing new coverage on Gilead Sciences, Inc. for its current position within the health care sector. Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. A copy of this report featuring Gilead Sciences, Inc. (NASDAQ: GILD) is available at: www.DividendSeeker.net/r/forbes/9898_GILD.
Dividend Seeker has released research on Amgen Inc. for its changing role within the health care sector. Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses. It focuses solely on human therapeutics and concentrates on medicines based on cellular and molecular biology. To access the full research report on Amgen Inc. (NASDAQ: AMGN) we welcome investors to visit: www.DividendSeeker.net/r/forbes/e96b_AMGN.
More About Dividend Seeker
For those looking to grow their portfolio and increase their net worth, Dividend Seeker is the right choice. Simplify your due diligence process and access investing tools and tips to head-start your investments. Join the community, subscribe to our newsletter and begin to experience the power of information. The more relevant data you have, the more opportunities you discover.